18 citations
,
October 2016 in “European Journal of Pharmaceutics and Biopharmaceutics” The drug was successfully released into hair follicles using nanocarriers.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
36 citations
,
January 2016 in “The journal of investigative dermatology/Journal of investigative dermatology” The document concludes that understanding genetic mutations in the PI3K-AKT-mTOR pathway can lead to better diagnosis and treatment for certain genetic skin disorders.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
May 2025 in “Pakistan Armed Forces Medical Journal” Dithranol is more effective than Tacrolimus for hair regrowth in alopecia areata.
1 citations
,
December 2024 in “Science, Engineering and Health Studies” Nanocomposite patches improve drug delivery through the skin, offering controlled release and fewer side effects.
September 2022 in “Zenodo (CERN European Organization for Nuclear Research)” 319 citations
,
March 2023 in “Science Advances” A wearable patch speeds up healing of chronic wounds by monitoring and treating them.
273 citations
,
May 2017 in “The Lancet” Some drugs can cause rare but potentially deadly skin reactions, and early treatment and avoiding the drug again are key.
2 citations
,
September 2022 in “Annals of Oncology” Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.
26 citations
,
October 2007 in “Experimental Dermatology” L-Carnitine-L-tartrate may help hair grow and prevent hair loss.
160 citations
,
April 2012 in “Journal of Cellular and Molecular Medicine” Telocytes might help with skin repair and regeneration.
January 2023 in “RSC Advances” The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
February 2021 in “Research Square (Research Square)” The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.
129 citations
,
January 1977 in “Hormone and metabolic research” Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.
65 citations
,
February 2015 in “Neuro-Oncology” Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.
February 2023 in “Reactions Weekly” 2 citations
,
April 2023 in “Journal of Psoriasis and Psoriatic Arthritis” Early diagnosis and treatment are crucial to prevent permanent hair loss from TNFα inhibitors in scalp psoriasis.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
91 citations
,
July 2004 in “Journal of Biological Chemistry” Overexpressing SSAT enzyme reduces prostate tumor growth in mice.
2 citations
,
November 2023 in “Acta dermato-venereologica” Tofacitinib is effective and safe for treating alopecia areata with a good drug survival rate.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” 42 citations
,
August 2016 in “Nanomedicine” The new adapalene formulation using TyroSpheres is more effective and less irritating for acne treatment.
16 citations
,
October 2013 in “Anais Brasileiros de Dermatologia” Scalp condition healed with prednisone and tacrolimus.
26 citations
,
September 2024 in “Perspectives in Clinical Research” Drug repurposing offers faster, cheaper drug development but faces challenges like safety, ethics, and funding.
April 2022 in “Reactions Weekly”
February 2026 in “Preprints.org” New therapies and personalized approaches improve wound healing and patient quality of life.
January 2022 in “Drugs of Today”
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.